Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Blood (2024) 144 (Supplement 1): 853.

https://doi.org/10.1182/blood-2024-201644

Published: 2024

Journal Articles

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Steven Le Gouill, Virginie de Wilde, Toby A. Eyre, Mary B. Callanan, Gandhi Damaj, Alexis Claudel, Adrien Chauchet, Roch Houot, Ronan Le Calloch, Victoria Cacheux, Marc André, Franck Morschhauser, Barbara Burroni, David John Lewis, Benoit Tessoulin, Aurore Touzart

Blood (2024) 144 (Supplement 1): 745.

https://doi.org/10.1182/blood-2024-194357

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Ronit Gurion, Irit Avivi Mazza, Catherine Thieblemont, Won Seog Kim, Andras Masszi, Alejandro Martín García-Sancho, Zsolt Nagy, Benoit Tessoulin, Ana Jimenez Ubieto, Po-Shen Ko, Daniel Alan Kerr, II, Edwin E. Jeng, Satya Siddani, Neha Joshi, Neha Dixit, Mariana Sacchi, Pegah Jafarinasabian, Abraham Avigdor

Blood (2024) 144 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2024-199301

Published: 2024

Journal Articles

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Yannick Le Bris, Barbara Burroni, Marguerite Fournier, Morgane Cheminant, Sara Ek, Eva Hoster, Marie-Helene Delfau-Larue, Clémentine Sarkozy, Mary B. Callanan, Benoit Tessoulin, David Chiron, Martin Dreyling, Mats Jerkeman, Steven Le Gouill, Olivier Hermine

Blood (2024) 144 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2024-199152

Published: 2024

Journal Articles

Early Metabolic Response and Tmtv Are Key Predictors of Control of Relapse/Refractory Follicular Lymphoma Treated with CAR-T Cells : Preliminary Results from the French Descar-T Registry

Yassine Al Tabaa, Xavier Pallard, Loic Ysebaert, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Guillaume Cartron, Catherine Thieblemont, Didier Blaise, Cedric Rossi, Francoise Kraeber-Bodere, Benoit Tessoulin, Fabien Le Bras, Olivier Hermine, Emelie Van Zele, Vivien Dupont, Romain Ricci

Blood (2024) 144 (Supplement 1): 7131.

https://doi.org/10.1182/blood-2024-200968

Published: 2024

Journal Articles

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Marion Aymard, Morgane Cheminant, Roch Houot, Anne Cuozzo, Elodie Gat, Catherine Thieblemont, Laure Ricard, Louise Roulin, Krimo Bouabdallah, Violaine Safar, Stephanie Guidez, Amandine Fayard, Gabriel Brisou, Loic Ysebaert, Olivier Hermine, Benoit Tessoulin, Charles Herbaux, Steven Le Gouill, Clementine Sarkozy

Blood (2024) 144 (Supplement 1): 239.

https://doi.org/10.1182/blood-2024-198920

Published: 2024

Journal Articles

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Benoit Tessoulin, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Cedric Rossi, Caroline Milin, Ludovic Fouillet, Charles Herbaux, Emmanuelle Tchernonog, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Steven Le Gouill

Blood (2024) 144 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2024-206778

Published: 2024

Journal Articles

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Blood (2024) 144 (3): 262–271.

https://doi.org/10.1182/blood.2024023944

Published: 2024

Includes: Supplemental data

Journal Articles

Unraveling MCL biology to understand resistance and identify vulnerabilities

clémentine Sarkozy, Benoit Tessoulin, David Chiron

Blood blood.2023022351.

https://doi.org/10.1182/blood.2023022351

Published: 2024

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 981.

https://doi.org/10.1182/blood-2023-181627

Published: 2023

Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 669.

https://doi.org/10.1182/blood-2023-181942

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Blood (2023) 142 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2023-180743

Published: 2023

Journal Articles

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Jurik A Mutter, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Stefan K. Alig, Mark P. Hamilton, Brian J. Sworder, Benoit Tessoulin, Jan Boegeholz, Timothy Flerlage, Jamie E. Flerlage, Michael S. Binkley, Takeshi Sugio, Cédric Rossi, Mari Olsen, Chih Long Liu, Steven Le Gouill, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 245.

https://doi.org/10.1182/blood-2023-186853

Published: 2023

Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 436.

https://doi.org/10.1182/blood-2023-179818

Published: 2023

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Blood (2023) 142 (Supplement 1): 170.

https://doi.org/10.1182/blood-2023-178030

Published: 2023

Journal Articles

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Clementine Sarkozy, Mary Callanan, Catherine Thieblemont, Lucie Oberic, Barbara Burroni, Krimo Bouabdallah, Gandhi Laurent Damaj, Benoit Tessoulin, Vincent Ribrag, Roch Houot, Franck Morschhauser, Victoria Cacheux, Vincent Delwail, Violaine Safar, Remy Gressin, Morgane Cheminant, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 980.

https://doi.org/10.1182/blood-2023-174416

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2023-180048

Published: 2023

Journal Articles

Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group

Benoit Tessoulin, Julien Depaus, Pierre Feugier, Ludovic Fouillet, Julie Abraham, Sandy Amorin, Fabrice Jardin, Franck Morschhauser, Catherine Thieblemont, François-Xavier Gros, Bertrand Joly, Hacene Zerazhi, Sophie Bernard, Adrien Chauchet, Stéphane Vigouroux, Christophe Bonnet, Sarah Bailly, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 3094.

https://doi.org/10.1182/blood-2023-173265

Published: 2023

NARROW

Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Early Metabolic Response and Tmtv Are Key Predictors of Control of Relapse/Refractory Follicular Lymphoma Treated with CAR-T Cells : Preliminary Results from the French Descar-T Registry

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Unraveling MCL biology to understand resistance and identify vulnerabilities

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only